Objective: A comparative assessment of treatment alternatives for T1N0 anal canal cancer has never been conducted. We compared the outcomes associated with the treatment alternatives-chemoradiotherapy (CRT), radiotherapy (RT), and surgery or ablation techniques (surgery/ablation)-for T1N0 anal canal cancer.
T he incidence rates for anal canal cancer in the United States have doubled over the past 10 years. 1 If diagnosed and treated early, that is, at stage T1N0 (when the tumor is <2 cm in diameter [T1] with no regional lymph node metastasis [N0]), anal canal cancer has an observed 5-year patient survival rate of approximately 71%, compared with lower 5-year observed survival (approximately 50%) for tumors larger than 5 cm across. 2 Tumors <2 cm in diameter are curable in approximately 90% of the cases, whereas tumors larger than 5 cm are curable in fewer than 80% of the cases. 3, 4 T1N0 anal canal cancer is typically treated with radiotherapy (RT), chemoradiotherapy (CRT), or surgery or ablation techniques such as cryosurgery (this will be referred to as "surgery/ablation" throughout the paper). Several randomized clinical trials have shown the benefits of CRT over RT; however, none of those studies focused specifically on T1N0 anal canal cancer. [5] [6] [7] [8] [9] Some studies, mostly retrospective, have shown that external-beam RT alone, brachytherapy alone, or a combination of the 2, is efficacious for T1N0 cancer. [10] [11] [12] Other studies have suggested CRT for the management of early-stage anal canal cancer. 13 A study by Klas et al 14 showed that in patients treated for T1N0 anal cancer, CRT offered outcomes equivalent to those achieved with surgery-only therapy. In addition to these equivocal reports for CRT and RT, the outcomes associated with surgery/ablation for T1N0 tumors have never been evaluated in a clinical trial. According to the National Comprehensive Cancer Network guidelines, CRT is currently the primary therapy and standard of care for T1N0 anal canal cancer. 15 Yet, no rationale for the use of CRT in these patients is provided in the guidelines. Given that CRT has associated side effects, RT or surgery/ablation may be associated with fewer long-term side effects and yield better overall outcomes in these patients.
Uncertainty regarding the optimal treatment options for T1N0 anal canal cancer provides a strong rationale for comparing the outcomes for these treatment strategies. Moreover, economic outcomes including cost-effectiveness can be an important consideration in the treatment selection process. Therefore, the purpose of this study was to evaluate the clinical outcomes, in terms of survival, associated with CRT, RT, and surgery/ablation for T1N0 anal canal cancer. Furthermore, we estimated the cost-effectiveness of treatment alternatives for these patients from a payer perspective.
MATERIALS AND METHODS

Data Source and Cohort Identification
We conducted a retrospective cohort analysis using the Surveillance, Epidemiology and End Results (SEER) registries that collect demographic, and cause-of death information for patients with cancer and Medicare longitudinal data, with claims for all covered fee-for-service health care from the time of eligibility to death. The SEER-Medicare database is the result of the linkage of 2 large population-based sources of data: cancer registry data from the National Cancer Institute's sponsored cancer registries (SEER program) and Medicare claims from the Center for Medicare and Medicare and Medicaid Services (CMS). Additional details of the SEERMedicare database have been documented elsewhere. 16 Patients diagnosed with T1N0 anal canal cancer between January 1, 1992 and December 31, 2009, were included in our study. We identified these patients using the ICD-O-3 site code of C21.0, C21.1, and C21.8 for anus, anal canal, and anorectum. The patients with anal margin tumor (ICD-O-3 code C44.5) were not included in this study. To identify patients with T1N0 anal cancer, the American Joint Committee on Cancer classification of malignant tumors (ie, tumor, node, metastasis staging) was not available in the SEER data for the patients diagnosed between 1992 and 2004. A T1N0 stage variable for those patients was created using (1) information on the size of the primary tumor, (2) extent of spread to nearby lymph nodes, and (3) tumor metastasis to other organs of the body.
The study population was limited to patients aged 66 years or older who had been diagnosed with pathologically confirmed anal cancer between 1992 and 2009 in SEER-linked Medicare database. The data were limited to patients older than 66 years to allow for a 1-year period after Medicare enrollment (age, 65 y) during which comorbidities could be recorded in claims files for the period before cancer diagnosis. Patients with unknown diagnosis months or diagnosis at autopsy or by death certificate only, or death date mismatch by SEER and Medicare datasets were excluded. We also identified noncancer cohort from the SEER-Medicare database, these were the patients identified from a 5% sample of Medicare beneficiaries. These patients were identified to estimate cancer-related costs. The detailed patient selection algorithm is presented in Figure 1 .
The institutional review boards at The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston considered this research activity exempt and a waiver for informed consent was approved.
Patient Selection and Treatment Identification
The inclusion criteria for the study were (1) patients must have been 66 years or older and enrolled in Medicare at the time of diagnosis, (2) must have had continuous parts A and B coverage during the entire observation period, and (3) must have had histologically confirmed anal cancer. We excluded the patients (1) if they were enrolled in Medicare managed care, and (2) if they were diagnosed only at death or if the month of their diagnosis was unknown.
After applying our inclusion and exclusion criteria, we identified 190 patients who received primary treatment for T1N0 anal canal cancer. As the purpose of the analysis was to identify first-line therapy (as opposed to therapy for tumor progression or tumor recurrence), initial treatment was defined using Medicare administrative codes for surgery (ie, local excision) or ablation (eg, cryosurgery, laser surgery), RT, and CRT posted in the billing records within 180 days after the time of diagnosis. Using the Current Procedural Terminology codes associated with the treatment alternatives, we identified patients treated with surgery/ablation, RT, or CRT (detailed treatment selection codes are provided in the Appendix, Supplemental Digital Content 1, http://links.lww.com/AJCO/ A148).
Treatment Effectiveness
Treatment effectiveness was defined in terms of survival duration from date of initial diagnosis.
Cost Estimation
We used the Medicare payer perspective to estimate the treatment costs for each patient by adding the amounts reimbursed by Medicare beginning from the date of receipt of treatment to death. Total costs of care were estimated as the sum of Medicare payments for cancer-related care claims for health care services. The cancer-related costs were estimated by subtracting the costs for the noncancer cohort from the costs for the cancer cohort. All costs were adjusted to the 2014 dollar amount using Medicare adjustment factors. 17 A separate set of adjustment factors were used to adjust the costs for Medicare Part A and Part B.
For cancer-related cost estimation, we matched cancer patients with the noncancer cohort by age and sex by assigning the same index date (ie, both cases and controls were monitored from the date of cancer detection until their death or the end of Medicare claims).
Statistical Analysis
Univariate Analysis
For the purpose of univariate analysis, the w 2 test was used to compare the demographic and clinical characteristics among the patients who received surgery/ablation, RT, or CRT for T1N0 anal canal cancer.
Survival analysis
The purpose of the survival analysis was to compare overall survival stratified by treatments. Overall survival duration was defined as the time from the cancer diagnosis date until the patient's death. We censored the outcome data for the patients who were still alive at the end of follow-up period. We created Kaplan-Meier survival curves to compare survival duration following different primary treatments (surgery/ ablation, RT, or CRT) among the study patients. We used the log-rank test to compare the unadjusted survival rates. A parametric regression model was used to predict survival. This model assumed that the median survival time followed the Weibull distribution, using age and sex as independent variables to predict the median survival time. 18 A predictive equation was then derived from the model to estimate the patients' life expectancy. In addition, we compared survival by treatment strategies using the Cox proportional hazards model, controlling for demographic and clinical explanatory variables, using the propensity score adjustment method. 19 A propensity score is a measure of the likelihood of a subject's being assigned to a particular treatment group conditional on observed baseline characteristics. 19 It has been reported in the literature that the adjustment using a propensity score mitigates the bias of the background covariates and may also control for biases introduced by unknown or unmeasured covariates associated with measured factors. 20 For propensity adjustment, we used covariate adjustment using propensity scores. 21 Using this approach, the outcome variable was regressed on an indicator variable denoting treatment status and the estimated propensity score. For this, we selected a logistic regression model. The effect of treatment (adjusted odds ratio) was determined using the estimated regression coefficient from the fitted regression model. We adjusted for the covariates-age at diagnosis, marital status, geographic location of residence, and comorbidity in the logistic regression model. We reported the hazard ratios with 2-sided P-values and 95% confidence intervals.
Cost-Effectiveness Analysis and Uncertainty Analysis
Costs and cost-effectiveness were estimated by calculating the mean for each treatment strategy. The incremental costeffectiveness ratio (ICER)
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DEffectiveness was estimated to evaluate the relative value of a given treatment to the next less costly alternative. Confidence intervals for the ICERs were generated using the net benefit regression approach. 22, 23 All future costs and outcomes were discounted using a discount rate of 3%.
RESULTS
Patient Characteristics
A univariate analysis of patient demographic and clinical characteristics by treatment group is presented in Table 1 proportion of female patients in the study cohort was higher than the proportion of male patients. The proportion of unmarried patients in the study cohort was higher than that of married patients. Geographically, the Southwest region had a higher percentage of T1N0 anal canal cancer patients than the Midwest and Northeast regions.
Survival Analysis
There was no significant difference in overall survival between the treatment groups as predicted by the KaplanMeier curves (log-rank test, P = 0.3186) (Fig. 2) . In the unadjusted Cox proportional hazards model, the hazard ratio of death for patients who received CRT was 1.433 (95% confidence interval [CI], 0.675-3.042) and those who received RT was 1.836 (95% CI, 0.824-4.093) compared with the patients who were treated using surgery/ablation (Table 2) ; however, this relationship did not reach statistical significance. When adjusted for patient demographic characteristics, the hazard ratio of death for the patients who received CRT was 1.168 (95% CI, 0.768-3.623), and that for the patient who received RT was 2.075 (95% CI, 0.895-4.811) than the patients who were treated using surgery/ablation. When adjusted for propensity scores, the results changed slightly. However, none of these relationships reached statistical significance.
Cost-Effectiveness Analysis
The results of the cost-effectiveness analysis are presented in Table 3 . In our study cohort, the mean cost associated with surgery/ablation was $29,210, far less than the average costs associated with CRT (mean cost, $46,350) or RT only (mean cost, $49,400). CRT was associated with an average survival of 7.72 years, followed by surgery/ablation (7.60 y) and RT (7.08 y). The ICER associated with CRT compared with surgery was $142,883 per life year (LY) gained (95% CI, $125,401/LY gained and $163,449/LY gained), respectively.
RT cost more than the other strategies and yielded fewer LYs, that is, RT was dominated by other treatment strategies.
DISCUSSION
This is the first study to evaluate the clinical and economic outcomes of treating T1N0 anal canal cancer by comparing the alternatives of surgery/ablation, CRT, and RT. We found that there was no statistically significant difference in overall survival (both unadjusted and when adjusted using propensity scores) among patients who were treated using surgery/ablation versus those treated with RT alone or CRT.
When we estimated cost-effectiveness of treatment alternatives using lifetime treatment costs and mean survival time, we found that RT was associated with higher costs and conferred fewer average LYs than CRT and surgery did. This trend (ie, higher cost of RT compared with CRT) might have occurred due to higher cost associated with subsequent recurrence in patients undergoing RT only. 24 This possible rationale was based on findings by Zilli and colleagues who found that patients receiving CRT had higher survival when compared with patients receiving RT alone. However, locoregional control rates were 100% and 89% in the CRT and radiationonly groups, respectively. We found that when the willingnessto-pay threshold of US$100,000 per LY 25 is to be considered as the maximum acceptable incremental cost-effectiveness ratio then surgery was considered cost-effective.
To our knowledge, only 2 previous studies have performed a comparative assessment of the treatments for T1N0 anal canal cancer. In their study, Klas and colleagues treated 7 patients surgically and 7 patients using a combination modality. The 5-year survival rate in the CRT group was 63% compared with 60% in the surgery group. 14 In 29 patients with T1N0 anal canal cancer, Zilli et al 24 treated 22 patients with CRT and 7 patients with RT only. At a median follow-up of 62.5 months, locoregional control was 100% and 89% in the CRT and RT groups, respectively. The 5-year actuarial cancerspecific survival rates for the patients treated with RT alone and CRT were 88.5% ± 4.5% and 94.9% ± 2.9%, respectively. In both these studies, it was shown that CRT is associated with better outcomes in terms of 5-year survival than CRT and surgery; however, similar to our analysis, no statistically significant difference was observed due to the small sample size.
Our analysis is the first to report cost-effectiveness for the alternative treatment selection options for T1N0 anal canal tumors. The purpose of cost-effectiveness analysis is estimation and not hypothesis testing. Thus, ignoring the nonsignificant association between the treatment strategies, we estimated the incremental cost-effectiveness, where we found that CRT compared with surgery resulted in an ICER of $142,833/LY gain. When this ICER is compared with the commonly accepted willingness-to-pay threshold of $100,000/ LY gain in the United States, CRT would not be considered a cost-effective strategy.
Our study is not without limitations. The retrospective design of our analysis had the limitations inherent to this design. We combined the patients who were treated surgically or using ablation techniques to ensure that we have adequate sample size for the analysis. As ablation techniques are not currently considered standard of care for invasive anal canal carcinoma, questions may be raised about the appropriateness of the treatment approach in these patients, patient selection, and the accuracy of their diagnosis. Furthermore, there are no data on preference-based quality of life or functional outcomes after receiving treatment for anal cancer. Therefore, we did not evaluate clinical outcomes in terms of quality-adjusted life years. The results pertain only to patients 66 years or older, and thus cannot be generalized to the overall US population as this population has a higher expected treatment cost owing to more comorbidities when compared with the younger population. Another limitation of our study was the relatively small sample size. We believe that this limitation may have contributed to insufficient statistical power, which could explain in part why none of the relationships in our survival analysis reached statistical significance.
CONCLUSIONS
Our study is the first to evaluate clinical and economic outcomes associated with T1N0 anal canal cancer treatment. Although the association did not reach statistical significance, we found that patients who were treated surgically might incur less costs, and have similar outcomes to those treated using CRT or RT (ie, surgery might be a cost-effective use of health care resources). The economic burden of anal cancer is substantial 26 ; therefore, it is crucial to explore this finding further in this era of limited health care resources. The analysis must be revised as more data emerge or outcomes from clinical trials become available. Owing to an increased awareness of cancer screening using anal cytology testing and digital anorectal 
